According to the "National News Network" report of Voice of China, the National Food and Drug Administration's Drug Evaluation Center said today that it encourages clinical value-oriented drug innovation and will further strengthen information disclosure.
The Drug Evaluation Center of the State Food and Drug Administration released the "2012 China Drug Evaluation Report" on the 28th. Zhang Peipei, director of the Drug Evaluation Center, introduced the professional drug evaluation work to the public in simple language.
Zhang Peipei: It is the responsibility of this institution to explain to patients and the public why this drug can be marketed, and the scientific basis for the listing; to provide doctors and relevant clinical institutions with instructions for drug use; to explain to applicants the basis for approval or disapproval.
In 2012, the Food and Drug Administration approved the production of 615 drugs, including three innovative drugs, mainly distributed in the field of anti-tumor, cardiovascular and vascular diseases. Zhang Peipei said that in the process of drug evaluation, the limited resources should be inclined to the most demanded aspects of the public.
Zhang Peipei: Focus on the research and development of drugs that have a good therapeutic effect on China's major disease spectrum, children's drugs, and rare disease drugs, and implement full supervision of major national special varieties to make the review work better implement the national drug innovation strategy. (Han Xiu)
Foot Stand,Plastic Bottom Feet Bar,Plastic Luggage Feet,Luggage Foot Stand
GUANGDONG SUNDES LUGGAGE ACCESSORY TECHNOLOGIES CO.,LTD , https://www.sundes-global.com